Another article in Targeted Oncology mentioning le
Post# of 153773
(Total Views: 581)
Posted On: 12/21/2020 8:40:46 PM
Another article in Targeted Oncology mentioning leronlimab.
https://www.targetedonc.com/view/nci-combats-covid-19-issues
"Repurposing Cancer Drugs
Certain medications with activity in solid tumor and hematologic malignancies have also shown activity against symptoms of COVID-19.
The therapeutic benefit of leronlimab, which has gained traction with the FDA for the treatment of breast malignancies,7 had been demonstrated in patients with COVID-19 in the recent phase 2 CD10 trial (NCT04343651) for mild-to-moderate symptoms of COVID-19.8
“We have become very knowledgeable of leronlimab’s potential [in patients with COVID-19] due to our completed phase 2 trial for mild-to-moderate symptoms,” Nader Pourhassan, PhD, president and chief executive officer of CytoDyn, the company responsible for manufacturing the agent, said in a statement.
In November, a protocol had been filed with the FDA for a phase 2 clinical trial aimed to evaluate leronlimab as treatment of patients with COVID19 who are suffering from long-hauler symptoms. If successful, the treatment would be the first for patients experiencing lingering symptoms of the virus, who account for up to 10% of all patients with COVID-19."
https://www.targetedonc.com/view/nci-combats-covid-19-issues
"Repurposing Cancer Drugs
Certain medications with activity in solid tumor and hematologic malignancies have also shown activity against symptoms of COVID-19.
The therapeutic benefit of leronlimab, which has gained traction with the FDA for the treatment of breast malignancies,7 had been demonstrated in patients with COVID-19 in the recent phase 2 CD10 trial (NCT04343651) for mild-to-moderate symptoms of COVID-19.8
“We have become very knowledgeable of leronlimab’s potential [in patients with COVID-19] due to our completed phase 2 trial for mild-to-moderate symptoms,” Nader Pourhassan, PhD, president and chief executive officer of CytoDyn, the company responsible for manufacturing the agent, said in a statement.
In November, a protocol had been filed with the FDA for a phase 2 clinical trial aimed to evaluate leronlimab as treatment of patients with COVID19 who are suffering from long-hauler symptoms. If successful, the treatment would be the first for patients experiencing lingering symptoms of the virus, who account for up to 10% of all patients with COVID-19."
(1)
(0)